Beovu® (brolucizumab-dbll)

When requesting Beovu® (brolucizumab-dbll), the individual requiring treatment must be diagnosed with the following FDA-approved indication or the approved off-label compendial use and meet the specific coverage guidelines for the covered indication.

FDA-Approved Indication

Beovu is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Approved Off-Label Compendial Uses

- Diabetic retinopathy
- Neovascular glaucoma
- Retinopathy of prematurity
- Sickle cell neovascularization
- Choroidal neovascular conditions

Coverage Guidelines

For all approved indications the individual must meet the following criteria for approval:

- Beovu will be administered by or under the supervision of an ophthalmologist

Approval duration: 12 months

Dosing Recommendation

Beovu is administered by intravitreal injection.

The recommended dose of Beovu is 6 mg (0.05) monthly for the first three doses, followed by one dose of 6 mg every 8-12 week.

References

1. Beovu® [prescribing information]. Hanover, NJ: Novartis Pharmaceuticals; October 2019.
2. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. *Expert Opin Investig Drugs*. 2009;18(5):637-646.
3. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv Ophthalmol*. 2011;56(2):95-113.
4. Kinnunen K, Ylä-Herttuala S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. *Ann Med*. 2012;44(1):1-17.
5. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. *Curr Opin Ophthalmol*. 2010;21(2):112-117.

© 2019 eviCore healthcare. All rights reserved.